T-Cinno Bioscience (CEO Chan-seon Park) , an innovative anticancer drug development company, announced on the 28th that it was finally selected for the 'Scale-Up TIPS' support project hosted by the Ministry of SMEs and Startups.
"Scale-Up Tips" is a program that supports the growth of promising small and medium-sized venture companies by linking private investment with government research and development (R&D) funding. TCN Biosciences was selected upon recommendation from Scale-Up Partners, a privately held company, and will receive a total of 1.14 billion won in R&D funding over the next three years through this project.
Based on this support, Tcinno Bioscience plans to begin full-scale development of a protein degradation-based anticancer drug (Targeted Protein Degrader, TPD) discovered using its artificial intelligence (AI) new drug development platform, TxPchider™.
The company explained that the technology is attracting attention as a next-generation treatment option that can overcome resistance issues arising from existing EGFR/RAS-targeted anticancer drugs and antibody-drug conjugates (ADCs). Furthermore, the company plans to build a differentiated pipeline by incorporating new modalities based on its existing experience and technological prowess in developing small-molecule anticancer drugs, and pursue business expansion.
Park Chan-sun, CEO of T-Cinno Bioscience, said, “Through this project, we will develop a new anticancer drug that can overcome the limitations of EGFR/RAS targeted therapies, thereby providing better treatment opportunities to cancer patients and their families.”
Meanwhile, Ticino Bioscience, a bio venture established in 2020 with technology investment from the Korea Institute of Science and Technology (KIST), is developing new anticancer drugs based on protein degradation and small molecules. Its main pipeline, TXN10128 (ENPP1 inhibitor), is an innate immunity-based anticancer drug currently in Phase 1 clinical trials in Korea and is expected to receive orphan drug designation from the U.S. Food and Drug Administration (FDA) in 2025. Currently, the company is developing a ULK1 inhibitor and various TPD new drugs as follow-up pipelines.
- See more related articles
You must be logged in to post a comment.